首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

2084725

轉甲狀腺素類澱粉沉積症治療市場：依藥物類型、疾病類型、通路和地區分類。

Transthyretin Amyloidosis Treatment Market, By Drug Type, By Disease Type, By Distribution Channel, By Geography

出版日期: 2026年06月15日 | 出版商:

Coherent Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，轉甲狀腺素類澱粉沉積症治療市場規模將達到 121 億美元，到 2033 年將達到 204 億美元。預計 2026 年至 2033 年的複合年成長率將達到 7.8%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	121億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.80%	2033年市場規模預測：	204億美元

轉甲狀腺素類澱粉沉積症是一種罕見的遺傳性疾病，其進展緩慢，特徵是澱粉樣蛋白在全身器官和組織中異常積聚。轉甲狀腺素蛋白澱粉樣類澱粉沉積症主要分為兩類：遺傳性轉甲狀腺素類澱粉沉積症和野生型轉甲狀腺素類澱粉沉積症。遺傳性轉甲狀腺素類澱粉沉積症可進一步分為神經病變、心肌病及混合型。

轉甲狀腺素類澱粉沉積症樣變性的診斷包括影像檢查、組織病理學檢查以及分子和基因檢測。心臟生物標記，例如腦鈉肽N端前體（NT-proBNP）和肌鈣蛋白，在心臟中濃度異常升高，並伴隨澱粉樣蛋白沉積，這些標記可用於該疾病的診斷。在遺傳性轉甲狀腺素類澱粉沉積症的診斷中，需要進行轉甲狀腺素蛋白基因突變的基因檢測。

市場動態

預計在預測期內，用於治療轉甲狀腺素類澱粉沉積症的新療法的核准和上市將成為市場成長的主要驅動力。 2018年10月，Eidos Therapeutics公司憑藉其專有候選藥物AG10獲得了美國食品藥物管理局（FDA）授予的孤兒藥資格認定，該藥物適用於治療ATTR。

2018 年 10 月，Ionis Pharmaceuticals, Inc. 及其子公司 Akcea Therapeutics Inc. 在加拿大獲得批准，其產品 TEGSEDI™（inotersen 注射液）可用於治療患有遺傳性轉甲狀腺素類澱粉沉積症(hATTR) 的成年患者的 1 期或 2 期神經病變。

此外，預計未來將有更多目前正在研發用於治療轉甲狀腺素類澱粉沉積症的藥物獲得批准。因此，這條強大的研發管線可望推動市場成長。例如，葛蘭素史克公司正在開發GlaxoSmithKline Plc (2398852)† + 2315698†，聯合治療，用於治療類澱粉沉積症。該產品目前正處於 II 期臨床試驗階段。

本次調查的主要特點

本報告對全球轉甲狀腺素類澱粉沉積症治療市場進行了詳細分析，並給出了預測期（2026-2033 年）的市場規模和複合年成長率。
此外，它還指出了各個細分市場的潛在商機，並說明了該市場中一個有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
本報告根據以下參數分析了全球轉甲狀腺素類澱粉沉積症治療市場的主要參與者：公司概況、財務績效、產品系列、企業發展區域、分銷策略、關鍵發展和策略。
本報告提供的見解將使企業負責人和經營團隊能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份「全球轉甲狀腺素類澱粉沉積症變性治療市場」報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用各種策略矩陣來分析全球轉甲狀腺素類澱粉沉積症治療市場，從而簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Alnylam Pharmaceuticals, Inc.
- Pfizer, Inc.
- Prothena Corporation Plc.
- GlaxoSmithKline Plc.
- Ionis Pharmaceuticals, Inc.
- Eidos Therapeutics
- SOM Innovation Biotech, SL
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI687

Transthyretin Amyloidosis Treatment Market is estimated to be valued at USD 12.1 Bn in 2026 and is expected to reach USD 20.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 12.1 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.80%	2033 Value Projection:	USD 20.4 Bn

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type.

Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.

Market Dynamics

Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR.

In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.

Key features of the study

This report provides in-depth analysis of the global transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026-2033)
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global transthyretin amyloidosis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global transthyretin amyloidosis treatment market

Market Segmentation

By Drug Type (Revenue, USD Bn, 2021-2033)
Tafamidis (Vyndaqel)
Patisiran (ONPATTRO)
Inotersen (TEGSEDI)
Others
By Disease Type (Revenue, USD Bn, 2021-2033)
Hereditary Transthyretin Amyloidosis
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
Wild Type Amyloidosis
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Alnylam Pharmaceuticals, Inc.
Pfizer, Inc.
Prothena Corporation Plc.
GlaxoSmithKline Plc.
Ionis Pharmaceuticals, Inc.
Eidos Therapeutics
SOM Innovation Biotech, S.L.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Transthyretin Amyloidosis Treatment Market, By Drug Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Tafamidis (Vyndaqel)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Patisiran (ONPATTRO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Inotersen (TEGSEDI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Transthyretin Amyloidosis Treatment Market, By Disease Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hereditary Transthyretin Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Polyneuropathy
  - Cardiomyopathy
  - Mixed Type
Wild Type Amyloidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Specialty Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Transthyretin Amyloidosis Treatment Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Alnylam Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Prothena Corporation Plc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- GlaxoSmithKline Plc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Ionis Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eidos Therapeutics
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- SOM Innovation Biotech, S.L.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views